For example, a soluble small-molecule AQP4 inhibitor could be administered in the hyperacute phase of stroke (first few hours) to delay astrocytic swelling, then washed out or counteracted by a second agent that promotes AQP4 activity in the subacute phase. This evidence concerns the gene AQP4 and Stroke.